{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T01:17:22Z","timestamp":1768094242343,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012456","name":"National Social Science Foundation of China","doi-asserted-by":"crossref","award":["18XGL019"],"award-info":[{"award-number":["18XGL019"]}],"id":[{"id":"10.13039\/501100012456","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s00228-023-03604-2","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T12:02:48Z","timestamp":1702641768000},"page":"249-259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety analysis of therapeutic drugs for breast cancer patients and construction of a predictive model for serious adverse drug reactions"],"prefix":"10.1007","volume":"80","author":[{"given":"Shuzhi","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biqi","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1937-7951","authenticated-orcid":false,"given":"Bianling","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,15]]},"reference":[{"key":"3604_CR1","first-page":"1","volume":"498","author":"World Health Organization (WHO)","year":"1972","unstructured":"World Health Organization (WHO) (1972) International drug monitoring: the role of national centres. Report of a WHO Meeting. World Health Organ Tech Rep Ser 498:1\u201325","journal-title":"World Health Organ Tech Rep Ser"},{"key":"3604_CR2","doi-asserted-by":"publisher","unstructured":"Molokhia M (2009) Improving reporting of adverse drug reactions: systematic review. CLEP 75. https:\/\/doi.org\/10.2147\/CLEP.S4775","DOI":"10.2147\/CLEP.S4775"},{"key":"3604_CR3","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S1470-2045(18)30094-9","volume":"19","author":"SN Weingart","year":"2018","unstructured":"Weingart SN, Zhang L, Sweeney M, Hassett M (2018) Chemotherapy medication errors. Lancet Oncol 19:e191\u2013e199. https:\/\/doi.org\/10.1016\/S1470-2045(18)30094-9","journal-title":"Lancet Oncol"},{"key":"3604_CR4","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.14009\/j.issn.1672-2124.2018.07.047","volume":"18","author":"Y Xuliang","year":"2018","unstructured":"Xuliang Y et al (2018) Adverse drug reactions to antineoplastic drugs and measures to prevent and treat them. Evaluation and Analysis of Drug-Use in Hospitals of China 18:1005\u20131008. https:\/\/doi.org\/10.14009\/j.issn.1672-2124.2018.07.047","journal-title":"Evaluation and Analysis of Drug-Use in Hospitals of China"},{"key":"3604_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA A Cancer J Clin"},{"key":"3604_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jncc.2022.02.002","volume":"2","author":"R Zheng","year":"2022","unstructured":"Zheng R, Zhang S, Zeng H et al (2022) Cancer incidence and mortality in China, 2016. Journal of the National Cancer Center 2:1\u20139. https:\/\/doi.org\/10.1016\/j.jncc.2022.02.002","journal-title":"Journal of the National Cancer Center"},{"key":"3604_CR7","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1158\/1078-0432.CCR-21-2600","volume":"28","author":"S Arora","year":"2022","unstructured":"Arora S, Narayan P, Osgood CL et al (2022) U.S. FDA drug approvals for breast cancer: a decade in review. Clin Cancer Res 28:1072\u20131086. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2600","journal-title":"Clin Cancer Res"},{"key":"3604_CR8","doi-asserted-by":"publisher","first-page":"9S","DOI":"10.2967\/jnumed.115.157834","volume":"57","author":"ES McDonald","year":"2016","unstructured":"McDonald ES, Clark AS, Tchou J et al (2016) Clinical diagnosis and management of breast cancer. J Nucl Med 57:9S-16S. https:\/\/doi.org\/10.2967\/jnumed.115.157834","journal-title":"J Nucl Med"},{"key":"3604_CR9","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM, Baselga J, Kim S-B et al (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372:724\u2013734. https:\/\/doi.org\/10.1056\/NEJMoa1413513","journal-title":"N Engl J Med"},{"key":"3604_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-074684","volume":"381","author":"C Taylor","year":"2023","unstructured":"Taylor C, McGale P, Probert J et al (2023) Breast cancer mortality in 500 000 women with early invasive breast cancer diagnosed in England, 1993\u20132015: population based observational cohort study. BMJ 381:e074684. https:\/\/doi.org\/10.1136\/bmj-2022-074684","journal-title":"BMJ"},{"key":"3604_CR11","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani C, Matsuda T, Di Carlo V et al (2018) Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. The Lancet 391:1023\u20131075. https:\/\/doi.org\/10.1016\/S0140-6736(17)33326-3","journal-title":"The Lancet"},{"key":"3604_CR12","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12282-019-01001-1","volume":"27","author":"Y Naito","year":"2020","unstructured":"Naito Y, Kai Y, Ishikawa T et al (2020) Chemotherapy-induced nausea and vomiting in patients with breast cancer: a prospective cohort study. Breast Cancer 27:122\u2013128. https:\/\/doi.org\/10.1007\/s12282-019-01001-1","journal-title":"Breast Cancer"},{"key":"3604_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11912-018-0710-1","volume":"20","author":"J Caron","year":"2018","unstructured":"Caron J, Nohria A (2018) Cardiac toxicity from breast cancer treatment: can we avoid this? Curr Oncol Rep 20:61. https:\/\/doi.org\/10.1007\/s11912-018-0710-1","journal-title":"Curr Oncol Rep"},{"key":"3604_CR14","doi-asserted-by":"publisher","first-page":"5149","DOI":"10.1002\/ehf2.13591","volume":"8","author":"W Chang","year":"2021","unstructured":"Chang W, Chen P, Lin H et al (2021) Risks of trastuzumab-related cardiotoxicity in breast cancer patients in Taiwan. ESC Heart Failure 8:5149\u20135158. https:\/\/doi.org\/10.1002\/ehf2.13591","journal-title":"ESC Heart Failure"},{"key":"3604_CR15","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2023.38.e56","volume":"38","author":"B Seo","year":"2023","unstructured":"Seo B, Yang M-S, Park S-Y et al (2023) Incidence and economic burden of adverse drug reactions in hospitalization: a prospective study in Korea. J Korean Med Sci 38:e56. https:\/\/doi.org\/10.3346\/jkms.2023.38.e56","journal-title":"J Korean Med Sci"},{"key":"3604_CR16","doi-asserted-by":"publisher","first-page":"4424","DOI":"10.1016\/j.apsb.2022.04.019","volume":"12","author":"J Wang","year":"2022","unstructured":"Wang J, Song H, Ge F et al (2022) Landscape of DILI-related adverse drug reaction in China Mainland. Acta Pharmaceutica Sinica B 12:4424\u20134431. https:\/\/doi.org\/10.1016\/j.apsb.2022.04.019","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"3604_CR17","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s40264-016-0446-5","volume":"39","author":"Y Hou","year":"2016","unstructured":"Hou Y, Li X, Wu G, Ye X (2016) National ADR monitoring system in China. Drug Saf 39:1043\u20131051. https:\/\/doi.org\/10.1007\/s40264-016-0446-5","journal-title":"Drug Saf"},{"key":"3604_CR18","volume-title":"The new materia medica","author":"X Chen","year":"2018","unstructured":"Chen X, Jin Y, Tang G (2018) The new materia medica, 18th edn. People\u2019s Medical Publishing House, Beijing","edition":"18"},{"key":"3604_CR19","doi-asserted-by":"publisher","unstructured":"Zhao Z, Dong Z, Liu J (2020) A quick guideline for drug evaluation and selection in Chinese medical institutions. herald of medicine. 39(11):1457\u20131465.\u00a0https:\/\/doi.org\/10.3870\/j.issn.1004-0781.2020.11.001","DOI":"10.3870\/j.issn.1004-0781.2020.11.001"},{"key":"3604_CR20","doi-asserted-by":"publisher","unstructured":"Lei S, Wang N, Ren B et al (2023) Safety analysis of antineoplastic drugs for lung cancer: a retrospective analysis based on Shaanxi Province in Western China. Expert Opin Drug Saf 1\u20137. https:\/\/doi.org\/10.1080\/14740338.2023.2193394","DOI":"10.1080\/14740338.2023.2193394"},{"key":"3604_CR21","unstructured":"Ministry of Health of The People\u2019s Republic of China (2011). Available at: https:\/\/www.nmpa.gov.cn\/xxgk\/fgwj\/bmgzh\/20110504162501325.html . Accessed March 24 2023"},{"key":"3604_CR22","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1002\/cncr.30547","volume":"123","author":"CR Friese","year":"2017","unstructured":"Friese CR, Harrison JM, Janz NK et al (2017) Treatment-associated toxicities reported by patients with early-stage invasive breast cancer: Breast Cancer Toxicities. Cancer 123:1925\u20131934. https:\/\/doi.org\/10.1002\/cncr.30547","journal-title":"Cancer"},{"key":"3604_CR23","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3389\/fphar.2019.00498","volume":"10","author":"FC Barcelos","year":"2019","unstructured":"Barcelos FC, de Matos GC, da Silva MJS et al (2019) Suspected adverse drug reactions related to breast cancer chemotherapy: disproportionality analysis of the Brazilian spontaneous reporting system. Front Pharmacol 10:498. https:\/\/doi.org\/10.3389\/fphar.2019.00498","journal-title":"Front Pharmacol"},{"key":"3604_CR24","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s40001-022-00839-0","volume":"27","author":"C Lin","year":"2022","unstructured":"Lin C, Cui J, Peng Z et al (2022) Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis. Eur J Med Res 27:201. https:\/\/doi.org\/10.1186\/s40001-022-00839-0","journal-title":"Eur J Med Res"},{"key":"3604_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejon.2008.10.003","volume":"13","author":"J Baker","year":"2009","unstructured":"Baker J, Ajani J, Scott\u00e9 F et al (2009) Docetaxel-related side effects and their management. Eur J Oncol Nurs 13:49\u201359. https:\/\/doi.org\/10.1016\/j.ejon.2008.10.003","journal-title":"Eur J Oncol Nurs"},{"key":"3604_CR26","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000324454","volume":"156","author":"E Syrigou","year":"2011","unstructured":"Syrigou E, Dannos I, Kotteas E et al (2011) Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol. Int Arch Allergy Immunol 156:320\u2013324. https:\/\/doi.org\/10.1159\/000324454","journal-title":"Int Arch Allergy Immunol"},{"key":"3604_CR27","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1016\/j.ejca.2008.09.026","volume":"44","author":"S Di Cosimo","year":"2008","unstructured":"Di Cosimo S, Baselga J (2008) Targeted therapies in breast cancer: where are we now? Eur J Cancer 44:2781\u20132790. https:\/\/doi.org\/10.1016\/j.ejca.2008.09.026","journal-title":"Eur J Cancer"},{"key":"3604_CR28","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1136\/jclinpath-2016-203847","volume":"70","author":"SS Ahmed","year":"2017","unstructured":"Ahmed SS, Thike AA, Zhang K et al (2017) Clinicopathological characteristics of oestrogen receptor negative, progesterone receptor positive breast cancers: re-evaluating subsets within this group. J Clin Pathol 70:320\u2013326. https:\/\/doi.org\/10.1136\/jclinpath-2016-203847","journal-title":"J Clin Pathol"},{"key":"3604_CR29","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/S0959-8049(99)00259-2","volume":"36","author":"J Chang","year":"2000","unstructured":"Chang J (2000) Chemotherapy dose reduction and delay in clinical practice: evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer 36:S11\u2013S14","journal-title":"Eur J Cancer"},{"key":"3604_CR30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/cncr.32472","volume":"126","author":"S Yadav","year":"2020","unstructured":"Yadav S, Karam D, Bin Riaz I et al (2020) Male breast cancer in the United States: treatment patterns and prognostic factors in the 21st century. Cancer 126:26\u201336. https:\/\/doi.org\/10.1002\/cncr.32472","journal-title":"Cancer"},{"key":"3604_CR31","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/jep.12184","volume":"20","author":"P Baldo","year":"2014","unstructured":"Baldo P, De Paoli P (2014) Pharmacovigilance in oncology: evaluation of current practice and future perspectives: pharmacovigilance in oncology and current practice. J Eval Clin Pract 20:559\u2013569. https:\/\/doi.org\/10.1111\/jep.12184","journal-title":"J Eval Clin Pract"},{"key":"3604_CR32","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1007\/s40264-022-01225-9","volume":"45","author":"M P\u00e9terv\u00e1ri","year":"2022","unstructured":"P\u00e9terv\u00e1ri M et al (2022) Network analysis for signal detection in spontaneous adverse event reporting database: application of network weighting normalization to characterize cardiovascular drug safety. Drug Saf 45:1423\u20131438","journal-title":"Drug Saf"},{"key":"3604_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1586\/17512433.2015.974555","volume":"8","author":"M Tuccori","year":"2015","unstructured":"Tuccori M, Montagnani S, Capogrosso-Sansone A et al (2015) Adverse reactions to oncologic drugs: spontaneous reporting and signal detection. Expert Rev Clin Pharmacol 8:61\u201375. https:\/\/doi.org\/10.1586\/17512433.2015.974555","journal-title":"Expert Rev Clin Pharmacol"},{"key":"3604_CR34","doi-asserted-by":"publisher","first-page":"957","DOI":"10.6004\/jnccn.2019.7286","volume":"17","author":"Z Veitch","year":"2019","unstructured":"Veitch Z, Khan OF, Tilley D et al (2019) Impact of cumulative chemotherapy dose on survival with adjuvant FEC-D chemotherapy for breast cancer. J Natl Compr Canc Netw 17:957\u2013967. https:\/\/doi.org\/10.6004\/jnccn.2019.7286","journal-title":"J Natl Compr Canc Netw"},{"key":"3604_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100693","volume":"31","author":"CL Bennett","year":"2021","unstructured":"Bennett CL, Hoque S, Olivieri N et al (2021) Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997\u20132019): a qualitative analysis from the Southern Network on Adverse Reactions (SONAR). EClinicalMedicine 31:100693. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100693","journal-title":"EClinicalMedicine"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03604-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-023-03604-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03604-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T10:03:27Z","timestamp":1707473007000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-023-03604-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["3604"],"URL":"https:\/\/doi.org\/10.1007\/s00228-023-03604-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,15]]},"assertion":[{"value":"5 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval for this study was received from the medicine and biomedical ethics committee of Xi\u2019an Jiaotong University (No. 2023\u20101631).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare that there is no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}